文献速递脑血管病

BCKDK:加剧脑缺血损伤的新型缺氧响应激酶

BCKDK, A Novel Hypoxia-Responsive Kinase That Exacerbates Cerebral Ischemia Injury.
PubMed 文献 · Stroke · 2026-07-23

该研究在小鼠原代皮层神经元氧糖剥夺模型和急性缺血性卒中模型中,发现脑缺血通过HIF-1α上调BCKDK,抑制BCKDH活性,阻碍支链氨基酸分解,加重能量缺乏和谷氨酸兴奋毒性。药理学或遗传学抑制BCKDK可减小梗死体积并改善神经元存活,提示BCKDK是脑缺血潜在治疗靶点。

要点

  • 脑缺血通过HIF-1α转录激活上调BCKDK,抑制BCAA分解代谢。
  • 抑制BCKDK可减轻缺血性损伤,减小梗死体积并改善神经元存活。
  • BCKDK是脑缺血的新型缺氧响应治疗靶点。

核心结论

  • BCKDK是缺氧响应因子,其上调驱动BCAA分解代谢障碍,是缺血性神经元损伤的关键机制。
  • BCKDK是脑缺血有前景的治疗靶点,得到体外和体内实验证据支持。

研究设计与样本

  • 研究使用小鼠原代皮层神经元氧糖剥夺模型和急性缺血性卒中模型脑组织。
  • 采用非靶向代谢组学和代谢流分析表征BCAA代谢。
  • 体内用BT2药理抑制或体外用RNA干扰敲低BCKDK。
  • 主要结局包括梗死体积、BCKDH酶活性、神经元活力和能量代谢及谷氨酸兴奋毒性标志物。

主要发现

  • 氧糖剥夺暴露的原代神经元较常氧对照显示BCAA分解代谢受损和显著BCAA积累。
  • 缺血小鼠脑组织中BCKDH活性显著受抑,BCKDK表达较假手术动物明显上调。
  • 药理学和遗传学抑制BCKDK均显著减轻脑缺血损伤,表现为梗死体积减小和神经元存活改善(各比较的95%CI和P值见原文)。
  • 机制上,缺血通过HIF-1α介导的转录激活诱导BCKDK表达,抑制BCAA转化为三羧酸循环底物,加剧能量缺乏和谷氨酸兴奋毒性。

临床怎么用

  • BCKDK可作为脑缺血治疗的潜在靶点,但需进一步临床研究验证。
  • BT2药理抑制BCKDK在动物模型中显示减轻缺血损伤的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alterations in circulating amino acid profiles have been observed in ischemic stroke patients; however, whether cerebral ischemia disrupts amino acid metabolism within brain tissue and whether this disruption contributes to cellular stress and cerebral injury remain unknown. This hypothesis-testing study investigates disrupted BCAA (branched-chain amino acid) catabolism as a key mechanism of ischemic brain damage and evaluates BCKDK (branched-chain α-keto acid dehydrogenase kinase) as a novel therapeutic target. METHODS: Mouse primary cortical neurons subjected to oxygen-glucose deprivation and brain tissue from a mouse acute ischemic stroke model were used as experimental systems. Untargeted metabolomics and metabolic flux analysis were used to characterize BCAA metabolism in both models. In vivo pharmacological inhibition or in vitro knockdown of BCKDK was performed using BT2 (3,6-dichlorobenzo[b]thiophene-2-carboxylic acid) treatment or RNA interference. Primary outcome variables included infarct volume, BCKDH (branched-chain α-keto acid dehydrogenase) enzyme activity, neuronal viability, and markers of energy metabolism and glutamate excitotoxicity. Between-group differences were evaluated using 1-way ANOVA; data are presented as mean ± SD with 95% CIs and corresponding P values. RESULTS: Metabolomics analysis of oxygen-glucose deprivation-exposed primary neurons revealed impaired BCAA catabolism and significant BCAA accumulation compared with normoxic controls. In ischemic mouse brain tissue, BCKDH activity was significantly suppressed, and BCKDK expression was markedly upregulated relative to sham-operated animals. Both pharmacological and genetic suppression of BCKDK substantially reduced cerebral ischemic injury, as evidenced by decreased infarct volume and improved neuronal survival (95% CI and P values per comparison). Mechanistically, ischemia-induced BCKDK expression via HIF-1α (hypoxia-inducible factor 1α)-mediated transcriptional activation, which inhibited BCAA conversion to tricarboxylic acid cycle substrates, thereby potentiating energy deficiency and glutamate excitotoxicity. CONCLUSIONS: These data identify BCKDK as a novel hypoxia-responsive factor whose upregulation drives disrupted BCAA catabolism as a key mechanism of ischemic neuronal injury. BCKDK represents a promising therapeutic target for cerebral ischemia, directly supported by both in vitro and in vivo experimental evidence presented here.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Liao B, Zhang F, Han C, et al. BCKDK, A Novel Hypoxia-Responsive Kinase That Exacerbates Cerebral Ischemia Injury. Stroke. 2026. PMID: 42488958. doi:10.1161/STROKEAHA.125.053856

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。